Ophthalmology Times: April 2023

Surgeon details training, experience with procedure that offers hope to patients.

Vitrectomy, lensectomy remain the primary surgical approaches for condition.

Efavirenz boosts cholesterol turnover in retina, brain.

Analysis signals up to 59% risk reduction in rate of vision loss compared with sham treatment at 12 months.

Physician discusses clinical presentations, treatment options for 2 cases.

Therapies to target geographic atrophy are in sight.

Pros and cons of anti-VEGF drugs and improved visualization of abnormalities in ROP.

Physicians are using the procedure to treat various stages of the disease.

Reducing treatment burden, finding something other than a shot a month is key.

As technology advances, innovations increase physician capabilities.

Physician outlines the latest emerging technologies to treat the condition.